A former backpacker accommodation is being transformed into a new eye health clinic in Broome, featuring three resident ophthalmologists available for 24-hour emergency support to service the north west of Western Australia. Read more
US approves first ever treatment for thyroid eye disease
Horizon Therapeutics has had its drug Tepezza, which is the first ever treatment for thyroid eye disease, approved by The US Food and Drug Administration (FDA). Read more
Patient receives first wireless retinal device implant
A surgeon at the University of Pittsburgh Medical Center (UPMC) has implanted the first patient in the US with a new wireless retinal device. Read more
Aussie corneal engineering research earns major backing
A Melbourne researcher has received a major funding boost to progress development of a tissue-engineered corneal endothelium for transplant, which could help overcome a global shortage of corneal donations in future. Read more
Gene responsible for ageing of eye found
In a discovery that could have significant implications for how age-related ocular diseases are diagnosed and treated, researchers have pinpointed a specific gene linked to the effect ageing has on the eye. Read more
Novartis secures approval for AMD drug in Australia
Australia’s ophthalmic community has welcomed the approval of Novartis’ latest therapy for neovascular age-related macular degeneration (nAMD). Advocates hope the decision will lift treatment adherence rates across the country. Read more
Opthea hits recruitment target for diabetic study
Melbourne biopharmaceutical company Opthea has completed the patient recruitment phase for the latest trial of its novel therapy for diabetic macular edema (DME). Read more
Major Melbourne study a world-first for AMD
An Australian-led study has received $5 million to undertake the world’s most intensive investigation into why a particular group of age-related macular degeneration (AMD) patients are at greater risk of vision loss. Read more
Novartis targets Europe for next-generation AMD treatment
Novartis’ new therapy for neovascular age-related macular degeneration (nAMD) has advanced part-way through the European regulatory process after winning the approval of independent advisors. Read more
Warmth may improve effectiveness of anti-VEGF injections
Inconsistent or ineffective age-related macular degeneration (AMD) treatments might be solved by an easy solution, according to new research from the California Institute of Technology. Read more